Polygiene (POLYG) Q4 2024 earnings summary

Executive summary

• Achieved strong growth in 2024, with Q4 sales up 45% year-over-year to SEK 44.7 million and full-year sales at SEK 156.9 million, demonstrating business scalability and profitability.

• Board proposed a dividend of SEK 0.05 per share, reflecting a new policy to return 40% of after-tax/net profit, subject to AGM approval.

• Expanded agent and distributor networks, made strategic partnerships in the US and China, and launched new products to support future growth.

• Strong cash flow and liquidity, with year-end cash at SEK 68.7 million and a debt-free balance sheet.

Financial highlights

• Q4 sales reached SEK 44.7 million (up from SEK 30.9 million); full-year sales were SEK 156.9 million (vs. SEK 113.5 million).

• Q4 gross margin was 76.1% (up from 70.6%); full-year gross margin was 70.8% (down from 73.2%).

• Q4 EBITDA was SEK 5.9 million (vs. -6 million); full-year EBITDA was SEK 19 million (vs. -12.2 million).

• Q4 EBIT was SEK 4.4 million (vs. -302.4 million, which included a SEK 295 million goodwill write-down last year); full-year EBIT was SEK 13.2 million.

• EPS for Q4 was SEK 0.20 (vs. -8.68); full-year EPS SEK 0.46 (vs. -8.31).

Outlook and guidance

• Positive outlook for 2025, with early signs of continued recovery, strong pipeline, and alignment across teams.

• March expected to be a key month for assessing Q1 performance due to early Chinese New Year.

• Focus remains on product development, market expansion, and maintaining profitability.